Optimal Injection Volume in Treatment of Tendinopathy A Systematic Review of Platelet Rich Plasma Injectate Volumes
Main Article Content
Keywords
Tendinopathy, Platelet Rich Plasma, systematic review, orthobiologics
Abstract
Background: Tendinopathy, a pathology of tendons characterized by inflammation and or degeneration, is a prevalent cause of disease and disability in active and working patients. Within the past decade, orthobiologic injections such as Platelet Rich Plasma (PRP) have become increasingly popular within the musculoskeletal physician’s practice for treatment of chronic tendinopathies. However, there is a lack of standardization of PRP preparation and injection protocols, leading to gaps in our knowledge regarding the optimal administration dosages to maximize treatment efficacy.
Purpose: This review aims to compile and evaluate the existing data for PRP injection volumes for various tendinopathies in hopes of contributing to standardization of PRP protocols, with a further goal of minimiz-ing waste of a costly therapeutic.
Study Design: Systematic Review
Methods: In June 2020, comprehensive electronic database searches were conducted by a medical librarian in Medline via PubMed, EMBASE (embase.com), CINAHL (EbscoHost), CENTRAL and Scopus according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data was extracted from studies meeting inclusion criteria on injection volumes and outcomes and grouped based on anatomic injection location.
Results: Twenty-eight studies were identified for inclusion in which ultrasound-guided intra-tendinous PRP injections were administered to patients to treat various tendinopathies. For all tendon locations, the mini-mum volume of injectate reported achieved positive clinical outcomes in patients compared to baseline. Conclusions: Despite its many benefits—tendon healing, pain relief, increased function—PRP can pose a significant financial burden to patients, with patients often having to pay for the full cost out-of-pocket due to lack of insurance coverage. This study provides evidence that PRP can be effective at smaller volumes, minimizing waste and the out-of-pocket cost to the patient. In addition, this study further stresses the impor-tance of protocol standardization.
Clinical Relevance: Though more data is needed, it is apparent that the minimum amount of injectate used clinically for various anatomic locations is enough for overall positive outcomes, and therefore can be the recommended dose given. As such, the authors have incorporated the minimum injection volume into their practice using the following volumes: Rotator Cuff-1 mL, Lateral or Medial Epicondyle-1.5 mL, Gluteal or Hamstring-3 mL, Patella-2 mL, Achilles-3 mL. Unfortunately, without more data available in the literature, the authors cannot make stronger recommendations at this time.
What is known about the subject: Among intralesional injections for the treatment of tendinopathy, PRP has shown positive results in multiple trials and has made its way into many musculoskeletal physicians’ practice. However, there is a significant lack of standardization in PRP protocols.
What this study adds to existing knowledge: While other reviews have highlighted the discrepancies amongst PRP protocols, our review is the first to examine injection volume and its effect on outcomes. We were able to suggest a minimum injectate amount for positive outcomes, either pain relief or improvement in the tendon appearance on imaging.
References
2. McCormick A, Charlton J, Fleming D. Assessing health needs in primary care. Morbidity study from general practice provides another source of information. BMJ 1995;310:1534.
3. Dean BJF, Dakin SG, Millar NL, Carr AJ. Review: Emerging concepts in the pathogenesis of tendinopathy. Surgeon 2017;15:349-54.
4. Tashjian RZ. Epidemiology, natural history, and indications for treatment of rotator cuff tears. Clin Sports Med 2012;31:589-604.
5. Tilley BJ, Cook JL, Docking SI, Gaida JE. Is higher serum cholesterol associated with altered tendon structure or tendon pain? A systematic review. Br J Sports Med 2015;49:1504-9.
6. Hopkins C, Fu SC, Chua E, et al. Critical review on the socio-economic impact of tendinopathy. Asia Pac J Sports Med Arthrosc Rehabil Technol 2016;4:9-20.
7. Loiacono C, Palermi S, Massa B, et al. Tendinopathy: Pathophysiology, Therapeutic Options, and Role of Nutraceutics. A Narrative Literature Review. Medicina (Kaunas) 2019;55.
8. Wilson JJ, Best TM. Common overuse tendon problems: A review and recommendations for treatment. Am Fam Physician 2005;72:811-8.
9. LaPrade RF, Dragoo JL, Koh JL, Murray IR, Geeslin AG, Chu CR. AAOS Research Symposium Updates and Consensus: Biologic Treatment of Orthopaedic Injuries. J Am Acad Orthop Surg 2016;24:e62-78.
10. Mautner K, Malanga GA, Smith J, et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM R 2015;7:S53-S9.
11. Dean BJ, Franklin SL, Carr AJ. A systematic review of the histological and molecular changes in rotator cuff disease. Bone Joint Res 2012;1:158-66.
12. Khan KM, Cook JL, Bonar F, Harcourt P, Astrom M. Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med 1999;27:393-408.
13. Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009;91:987-96.
14. Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther 2010;10:1415-26.
15. de Mos M, van der Windt AE, Jahr H, et al. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med 2008;36:1171-8.
16. Leong NL, Kator JL, Clemens TL, James A, Enamoto-Iwamoto M, Jiang J. Tendon and Ligament Healing and Current Approaches to Tendon and Ligament Regeneration. J Orthop Res 2020;38:7-12.
17. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med 2003;33:381-94.
18. Chahla J, Cinque ME, Piuzzi NS, et al. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. J Bone Joint Surg Am 2017;99:1769-79.
19. Beitzel K, Allen D, Apostolakos J, et al. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. J Knee Surg 2015;28:29-34.
20. Momaya AM, McGee AS, Dombrowsky AR, et al. The Cost Variability of Orthobiologics. Sports Health 2020;12:94-8.
21. Kesikburun S, Tan AK, Yilmaz B, Yasar E, Yazicioglu K. Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. Am J Sports Med 2013;41:2609-16.
22. Kim SJ, Kim EK, Kim SJ, Song DH. Effects of bone marrow aspirate concentrate and platelet-rich plasma on patients with partial tear of the rotator cuff tendon. J Orthop Surg Res 2018;13:1.
23. Ladermann A, Zumstein MA, Kolo FC, Grosclaude M, Koglin L, Schwitzguebel AJ. In vivo clinical and radiological effects of platelet-rich plasma on interstitial supraspinatus lesion: Case series. Orthop Traumatol Surg Res 2016;102:977-82.
24. Rha DW, Park GY, Kim YK, Kim MT, Lee SC. Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial. Clin Rehabil 2013;27:113-22.
25. Scarpone M, Rabago D, Snell E, et al. Effectiveness of Platelet-rich Plasma Injection for Rotator Cuff Tendinopathy: A Prospective Open-label Study. Glob Adv Health Med 2013;2:26-31.
26. Schwitzguebel AJ, Kolo FC, Tirefort J, et al. Efficacy of Platelet-Rich Plasma for the Treatment of Interstitial Supraspinatus Tears: A Double-Blinded, Randomized Controlled Trial. Am J Sports Med 2019;47:1885-92.
27. Behera P, Dhillon M, Aggarwal S, Marwaha N, Prakash M. Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. J Orthop Surg (Hong Kong) 2015;23:6-10.
28. Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. Br J Sports Med 2011;45:966-71.
29. Krogh TP, Fredberg U, Stengaard-Pedersen K, Christensen R, Jensen P, Ellingsen T. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med 2013;41:625-35.
30. Lim W, Park SH, Kim B, Kang SW, Lee JW, Moon YL. Relationship of cytokine levels and clinical effect on platelet-rich plasma-treated lateral epicondylitis. J Orthop Res 2018;36:913-20.
31. Martin JI, Atilano L, Merino J, et al. Platelet-rich plasma versus lidocaine as tenotomy adjuvants in people with elbow epicondylopathy: a randomized controlled trial. J Orthop Surg Res 2019;14:109.
32. Montalvan B, Le Goux P, Klouche S, Borgel D, Hardy P, Breban M. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up. Rheumatology (Oxford) 2016;55:279-85.
33. Fitzpatrick J, Bulsara MK, O’Donnell J, McCrory PR, Zheng MH. The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendinopathy: A Randomized, Double-Blind Controlled Trial Comparing a Single Platelet-Rich Plasma Injection With a Single Corticosteroid Injection. Am J Sports Med 2018;46:933-9.
34. Fitzpatrick J, Bulsara MK, O’Donnell J, Zheng MH. Leucocyte-Rich Platelet-Rich Plasma Treatment of Gluteus Medius and Minimus Tendinopathy: A Double-Blind Randomized Controlled Trial With 2-Year Follow-up. Am J Sports Med 2019;47:1130-7.
35. Lee JJ, Harrison JR, Boachie-Adjei K, Vargas E, Moley PJ. Platelet-Rich Plasma Injections With Needle Tenotomy for Gluteus Medius Tendinopathy: A Registry Study With Prospective Follow-up. Orthop J Sports Med 2016;4:2325967116671692.
36. Davenport KL, Campos JS, Nguyen J, Saboeiro G, Adler RS, Moley PJ. Ultrasound-Guided Intratendinous Injections With Platelet-Rich Plasma or Autologous Whole Blood for Treatment of Proximal Hamstring Tendinopathy: A Double-Blind Randomized Controlled Trial. J Ultrasound Med 2015;34:1455-63.
37. Abdelbary MB, A. Ultrasound guided injection in patellar tendinopathy; clinical outcomes of platelet-rich plasma compared to high-volume injection. The Egyptian Journal of Radiology and Nuclear Medicine 2018;49:1159-62.
38. Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. Am J Sports Med 2014;42:610-8.
39. Filardo G, Kon E, Di Matteo B, Pelotti P, Di Martino A, Marcacci M. Platelet-rich plasma for the treatment of patellar tendinopathy: clinical and imaging findings at medium-term follow-up. Int Orthop 2013;37:1583-9.
40. Kaux JF, Croisier JL, Forthomme B, et al. Using platelet-rich plasma to treat jumper’s knees: Exploring the effect of a second closely-timed infiltration. J Sci Med Sport 2016;19:200-4.
41. Scott A, LaPrade RF, Harmon KG, et al. Platelet-Rich Plasma for Patellar Tendinopathy: A Randomized Controlled Trial of Leukocyte-Rich PRP or Leukocyte-Poor PRP Versus Saline. Am J Sports Med 2019;47:1654-61.
42. Vetrano M, Castorina A, Vulpiani MC, Baldini R, Pavan A, Ferretti A. Platelet-rich plasma versus focused shock waves in the treatment of jumper’s knee in athletes. Am J Sports Med 2013;41:795-803.
43. Albano D, Messina C, Usuelli FG, et al. Magnetic resonance and ultrasound in achilles tendinopathy: Predictive role and response assessment to platelet-rich plasma and adipose-derived stromal vascular fraction injection. Eur J Radiol 2017;95:130-5.
44. de Jonge S, de Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: a double-blind randomized placebo-controlled trial. Am J Sports Med 2011;39:1623-9.
45. de Vos RJ, Weir A, van Schie HT, et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 2010;303:144-9.
46. Filardo G, Kon E, Di Matteo B, et al. Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: results at 4 years. Blood Transfus 2014;12:533-40.
47. Krogh TP, Ellingsen T, Christensen R, Jensen P, Fredberg U. Ultrasound-Guided Injection Therapy of Achilles Tendinopathy With Platelet-Rich Plasma or Saline: A Randomized, Blinded, Placebo-Controlled Trial. Am J Sports Med 2016;44:1990-7.
48. Dallaudiere B, Pesquer L, Meyer P, et al. Intratendinous injection of platelet-rich plasma under US guidance to treat tendinopathy: a long-term pilot study. J Vasc Interv Radiol 2014;25:717-23.
49. Park GY, Kwon DR, Cho HK, Park J, Park JH. Distribution of Platelet-rich Plasma after Ultrasound-Guided Injection for Chronic Elbow Tendinopathies. J Sports Sci Med 2017;16:1-5.
50. Loftus ML, Endo Y, Adler RS. Retrospective analysis of post-injection ultrasound imaging after platelet-rich plasma or autologous blood: observational review of anatomic distribution of injected material. AJR Am J Roentgenol 2012;199:W501-5.
51. Wilson JJ, Lee KS, Chamberlain C, et al. Intratendinous injections of platelet-rich plasma: feasibility and effect on tendon morphology and mechanics. J Exp Orthop 2015;2:5.
52. Daniels EW, Cole D, Jacobs B, Phillips SF. Existing Evidence on Ultrasound-Guided Injections in Sports Medicine. Orthop J Sports Med 2018;6:2325967118756576.
53. Finnoff JT, Hall MM, Adams E, et al. American Medical Society for Sports Medicine position statement: interventional musculoskeletal ultrasound in sports medicine. Clin J Sport Med 2015;25:6-22.